Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic liver disease.~* An estimated creatinine clearance of ≥ 60 mL/min.~* Serum alanine transaminase (ALT) or aspartate transaminase (AST) elevation must be above the upper limit of normal and below 5 times the upper limit of normal for patients with underlying liver disease; Child-Pugh score 5 to 9 (mild to moderate impairment).~* Patient must agree to practice effective contraception during the entire study period.~* Patient is willing to avoid strenuous physical activity from 24 hours prior to the study start, throughout the study, and for 2 weeks after the administration of the dose of study drug~* Patient is willing to avoid any alcohol consumption for the 24 hours prior to, and the 48 hours after administration of study drug; and avoid excessive alcohol consumption for the duration of the follow-up period.~* Patient must be able and willing to sign informed consent form.~Exclusion Criteria:~* Patient with clinically significant illnesses or recent hospitalization (within 60 days) which could compromise participation in the study in the judgment of the investigator, including: uncontrolled diabetes; active or uncontrolled infection; Confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.~* Patient with any other auto immune disease, major chronic inflammatory disease or syndrome requiring significant treatment within the past year.~* Patients who are pregnant or breast feeding~* Patient receiving or has received any investigational drug within 30 days prior (or is currently using an investigational device)~* Patients with prior (within 4 weeks) or concurrent treatment with oral steroids, or protein-based therapy (i.e. TNFa)~* Patients with positive urine screen for drugs of abuse except when receiving a prescribed medication for a known indication~* Patients with Grade 2 or above hepatic encephalopathy.~* Patients who donated blood or experienced a significant blood loss (\>450 mL) within 8 weeks of screening~* Patients with a history of bleeding varices within 12 weeks of screening.~* Patients with psychiatric illness or other condition that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): RTA 402
- 2 (Type: EXPERIMENTAL): RTA 402
- 3 (Type: EXPERIMENTAL): RTA 402

Based on this trial design, predict the completion outcome and termination type (if applicable).